Cash, cash equivalents, restricted cash and short-term investments totaled $207.5 million as of September 30, 2025. The current cash position, without accounting for anticipated revenue from ZEVASKYN, is expected to be sufficient to fund current and planned operations for over two years.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABEO:
- Abeona Therapeutics announces employee inducement grants
- Abeona Therapeutics announces permanent J-Code for ZEVASKYN
- Abeona Therapeutics appoints Gow as SVP, Head of Clinical Development
- Abeona Therapeutics announces ABO-503 gene therapy for XLRS selected by FDA
- Abeona, Children’s Hospital Colorado activate newest QTC for ZEVASKYN